| Volume 25, 2021 Articles |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
PreScription: The NASEM cBHT Report, Part 2
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 4
|
Cleanroom Cleanliness
Mulder Kyle
|
Jan/Feb 2021
Pg. 6-12
|
Gender Bias in the Treatment of Menopausal Women: I am Hot as Hell and Not Going to Take It Anymore, Part 2
DeRosa Angela
|
Jan/Feb 2021
Pg. 14-17
|
Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol
McKettrick Greg, Yoch Doug
|
Jan/Feb 2021
Pg. 18-23
|
Case Report: The Quest for a Palatable Compounded Metronidazole (Base) Suspension
McElhiney Linda F
|
Jan/Feb 2021
Pg. 24-28
|
Intravenous Admixture Preparation Considerations, Part 8: Ready-to-Use Preparations
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 31-38
|
Calculations
Stockton Shelly J
|
Jan/Feb 2021
Pg. 40
|
Acetaminophen (Paracetamol) 50 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 42
|
Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 43
|
Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 44
|
Cyclophosphamide 10 mg/mL in Oral-Plus or Simple Syrup Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 45
|
Diclofenac Sodium 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 46
|
Metronidazole 50-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 47
|
Design and Performance of an Inexpensive Water Activity Meter
Gilda Sagar S, Schober Joseph M, McPherson Timothy
|
Jan/Feb 2021
Pg. 48-51
|
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration
Lu Juan, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T
|
Jan/Feb 2021
Pg. 52-61
|
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
|
Jan/Feb 2021
Pg. 62-72
|
Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
|
Jan/Feb 2021
Pg. 73-81
|
Physical-chemical Stability of Compounded Sildenafil 100-mg Rapid-dissolving Tablets
Cheung Matthew, Zhao Fang, Dave Vivek S
|
Jan/Feb 2021
Pg. 82-87
|
PreScription: The Past (-->2020), The Present, and The Future (2021-->)
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 92
|
The Stanley Prostate-cancer Treatment Protocol for Erectile Dysfunction After Prostatectomy and/or Radiotherapy: A Case Report
McKettrick Greg, Yoch Doug
|
Mar/Apr 2021
Pg. 94-98
|
Compounding Pearls -- Wound Care: Drugs and Formulations for Dermal Healing
Riepl Mike
|
Mar/Apr 2021
Pg. 100-103
|
Experimental Multidisciplinary Approach Based on Compounded Capsule's Quality Evaluation for Pharmacy Undergraduate Courses
dos Santos Matheus Skrcek Ribeiro, de Lima Amanda Muniz dos Santos, Christoff Adriana de Oliveira, Teixeira Mariana Lopes, Carneiro Jaqueline
|
Mar/Apr 2021
Pg. 104-108
|
Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
|
Mar/Apr 2021
Pg. 109-113
|
Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice
Kelley Brian
|
Mar/Apr 2021
Pg. 115-124
|
Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 8: Humectants
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 126-128
|
Intravenous Admixture Preparation Considerations, Part 9-A: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 131-139
|
Calculations
Stockton Shelly J, Bui Phi H
|
Mar/Apr 2021
Pg. 140-141
|
Amlodipine 1-mg/mL in Oral Mix Suspension
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 142
|
Canine Soft Chew Base (Veterinary)
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 143
|
Eslicarbazepine Acetate 40-mg/mL in Ora-Plus with Ora-Sweet or Ora-Sweet SF Suspension
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 144
|
Levodopa/Carbidopa 5.0/1.25 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Mar/Apr 2021
Pg. 145
|
In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
|
Mar/Apr 2021
Pg. 146-155
|
Stability of Fagron's Phytobase Cream Compounded with Various Hormones
Wynn Tom, Taylor Sarah, Zander Clark
|
Mar/Apr 2021
Pg. 156-162
|
Stability of Extemporaneously Compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes
Walsh Andrea, Ziegler Blake, Lingertat-Walsh Karen, Law Shirley, Walker Scott E
|
Mar/Apr 2021
Pg. 163-168
|
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
|
Mar/Apr 2021
Pg. 169-175
|
PreScription: The Ethical Pharmacist
Allen Loyd V Jr
|
May/Jun 2021
Pg. 180
|
Pharmacy Technicians' Perceptions of Risk Reduction Strategies Implemented in Response to the Repetitive Strain Injury Associated with Sterile Compounding
Zamani Mazdak, Chan Kayin, Wilcox Julie
|
May/Jun 2021
Pg. 182-186
|
Insurance Considerations for the Pharmacy Professional
Jones Kirsten
|
May/Jun 2021
Pg. 190-195
|
A Simplified Method for Compounding Lidocaine Topical Gel: A Demonstration of Quality Assurance to Prevent Errors in 503A Pharmacies
Hall Essence, Levesque Dan, Rashid Mamoon, Mullins Randy, Hossain Mohammad Faisal
|
May/Jun 2021
Pg. 197-204
|
FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows
Brunner Scott
|
May/Jun 2021
Pg. 206-209
|
Quality Control: Testing for "Micromonsters": Viable Air and Surface Sampling in Aseptic Compounding
Mulder Kyle
|
May/Jun 2021
Pg. 211-216
|
Basics of Compounding: Excipients Used in Nonsterile Compounding: Diluents
Allen Loyd V Jr
|
May/Jun 2021
Pg. 218-221
|
Intravenous Admixture Preparation Considerations, Part 9-B: Error Prevention in Intravenous Admixture Preparation
Allen Loyd V Jr
|
May/Jun 2021
Pg. 222-229
|
Calculations
Stockton Shelly J
|
May/Jun 2021
Pg. 230-231
|
Levofloxacin 50-mg/mL in Ora-Plus and Strawberry Syrup Suspension
Allen Loyd V Jr
|
May/Jun 2021
Pg. 232
|
Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension
Allen Loyd V Jr
|
May/Jun 2021
Pg. 233
|
Tacrolimus 0.5 mg/mL in Ora-Plus and Simple Syrup Suspension
Allen Loyd V Jr
|
May/Jun 2021
Pg. 234
|
Temozolomide 10 mg/mL in Oral Mix SF Suspension
Allen Loyd V Jr
|
May/Jun 2021
Pg. 235
|
Stability Evaluation of Minoxidil in FOAMIL Foam Base with Bracketing Study Design
Lupatini Rodrigo, Sidhu Raman, Patel Harshad, Bichar Katia
|
May/Jun 2021
Pg. 236-240
|
In Vitro Release Tests of Ketoprofen from Pluronic Lecithin Organogel versus Lipoderm Using Immersion Cells and the Phoenix DB-6 Dry Heat Diffusion Tester
McKinney Rachael D, Dunbar Jacob R
|
May/Jun 2021
Pg. 241-245
|
Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags
Hui Ada, Yin Jian, Liu Wei, Zheng Kai
|
May/Jun 2021
Pg. 246-257
|
Study on the Optimal Conditions for Long-term Storage of Melatonin Powder as an In-hospital Preparation
Odanaka Keita, Kojima Hiroki, Nakagawa Naoto
|
May/Jun 2021
Pg. 258-262
|
PreScription: Endemics, Epidemics, and Pandemics
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 268
|
Growing a Compounding Practice: Successful Marketing to Underserved Populations
McKettrick Greg, Yoch Doug
|
Jul/Aug 2021
Pg. 270-274
|
Expecting the Expected: Planning Considerations for Cleanroom Construction
Roberts Patricia A, Kroon Laura
|
Jul/Aug 2021
Pg. 276-281
|
Compounding Pearls -- Wound Care: Drugs and Formulations for Dermal Healing, Part 2
Riepl Mike
|
Jul/Aug 2021
Pg. 282-287
|
Safety Aspects of Extemporaneous Prescriptions Prescribed by Latvian Healthcare Specialists
Kiselova Olga, Maurina Baiba, Sidlovska Venta
|
Jul/Aug 2021
Pg. 288-295
|
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Brunner Scott
|
Jul/Aug 2021
Pg. 296-297
|
Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 1
Higgins Doral (Neal) O, Prudom Melanie J, Summers Amy
|
Jul/Aug 2021
Pg. 298-302
|
Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 10: Rectal Suppository Bases
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 304-309
|
Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 311-317
|
Calculations
Stockton Shelly J
|
Jul/Aug 2021
Pg. 318
|
Apixaban 0.25-mg/mL Suspension for Enteral Feeding Tube
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 320
|
Atomoxetine 4-mg/mL Oral Solution/Suspension
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 321
|
BHR in PLO Gel (Benadryl, Haldol, and Reglan in Pluronic Lecithin Organogel)
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 322
|
Budesonide 0.0.25% Mucoadhesive Gel
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 323
|
Cyclopentolate Hydrochloride 0.5%, Phenylephrine HCl 2.5%, and Tropicamide 0.5% Ophthalmic Solution
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 324
|
Hydrocortisone 2-mg/mL in Oral Mix Suspension
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 325
|
Moh's Paste, Modified
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 326
|
Nifedipine 4.mg/mL in SyrSpend SF pH4 Cherry Flavored
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 327
|
Tacrolimus 0.1% Topical Microemulsion
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 328
|
Valsartan 4-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 329
|
Stability of Dexmedetomidine in Polyvinyl Chloride Bags Containing 0.9% Sodium Chloride Intended for Subcutaneous Infusions
Wolfe Amanda, Zhang Jeremy, Lapenskie Julie, Downar James, Kanji Salmaan
|
Jul/Aug 2021
Pg. 330-335
|
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
|
Jul/Aug 2021
Pg. 336-343
|
Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases
Teimouri Arezou, Yeung Pollen, Agu Remigius U
|
Jul/Aug 2021
Pg. 344-351
|
PreScription: Permissible Exposure Limits and United States Pharmacopeia Chapter <800>
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 356
|
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
|
Sep/Oct 2021
Pg. 358-362
|
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products
Uttaro Elizabeth, Zhao Fang, Schweighardt Anne
|
Sep/Oct 2021
Pg. 364-371
|
Compounding Pearls--Wound Care: Drugs and Formulations for Dermal Healing, Part 3: The Roles of Nitric Oxide, Sildenafil, and Naltrexone
Riepl Mike
|
Sep/Oct 2021
Pg. 372-377
|
Realities of Pharmaceutical Compounding in the Republic of Uzbekistan
Umarov Ulugbek, Zdoryk Oleksandr, Kolisnyk Sergii, Fatkhullaeva Muyussar
|
Sep/Oct 2021
Pg. 378-384
|
It's Time for a New Philosophy
Brunner Scott
|
Sep/Oct 2021
Pg. 386-387
|
Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2
Higgins Doral (Neal) O, Prudom Melanie J, Summers Amy
|
Sep/Oct 2021
Pg. 389-395
|
Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 11: Drug Tastes: Innate, Induced, and Improved
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 396-400
|
Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 11: Particulate Issues --- Silicone Oil in Vials, Cartridges, and Syringes
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 403-408
|
Calculations
Stockton Shelly J
|
Sep/Oct 2021
Pg. 410
|
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 412
|
Cilazapril 1-mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 413
|
Clonidine 0.01-mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 414
|
Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 415
|
Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 416
|
Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 417
|
Imipramine Hydrochloride 5-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 418
|
Mycophenolate Mofetil 50-mg/mL in Ora-Plus:Cherry Syrup Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 419
|
Sorafenib 20-mg/mL in Oil Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 420
|
Spironolactone 2-mg/mL or 2-5.mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 421
|
Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli
|
Sep/Oct 2021
Pg. 422-426
|
Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base
Lopalco Antonio, Lopedota Angela, Aurelio Fiorenza, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
|
Sep/Oct 2021
Pg. 427-430
|
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
|
Sep/Oct 2021
Pg. 431-439
|
PreScription: IJPC -- Twenty-Five Year Anniversary
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 444
|
Microwave Freeze-thaw Technique for Injectable Drugs: A Review Updated from 1980 to 2021
Hecq Jean-Daniel, Soumoy Laura, Closset Mélanie, Colsoul Marie-Lise, Jamart Jacques, Galanti Laurence
|
Nov/Dec 2021
Pg. 446-462
|
Glycopyrrolate Sorbitol Lollipops for Drooling: Two Case Reports
Agbi Kelechi E, Carvalho Maria, Vieira-Banov Fabiana
|
Nov/Dec 2021
Pg. 464-467
|
Compounding Pearls -- Wound Care: Drugs and Formulations for Dermal Healing, Part 4. Insulin
Riepl Mike
|
Nov/Dec 2021
Pg. 468-472
|
Hospital Compounding in Nigeria: A Review of Needs, Practice, and Suggestions for Pharmaceutical Dispensing Ciurriculum Development
Orubu Ebiowei Samuel F, Patani Bernard Opatimidi, Arhewoh Matthew Ikhuoria
|
Nov/Dec 2021
Pg. 475-481
|
Case Reports on the Use of Aloe Vera, Naltrexone, and Topiramate for the Treatment of Scars
Harris Kylie, Wright Edward
|
Nov/Dec 2021
Pg. 482-485
|
Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 12: Sorbents (Adsorbents and Absorbents)
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 486-489
|
Basics of Sterile Compounding: Intravenous Admixture Preparation, Part 12: United States Pharmacopeia Chapters Referenced in the Current United States Pharmacopeia Chapter <797> Pharmaceutical Compounding -- Sterile Preparations
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 491-496
|
Calculations
Stockton Shelly J
|
Nov/Dec 2021
Pg. 498
|
Domperidone 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 500
|
Kayexalate in Lactulose
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 501
|
Levetiracetam 50 mg/mL in Ora-Sweet and Ora-Plus Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 502
|
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 503
|
Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 504
|
Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 505
|
Quetiapine Fumarate 10 mg/mL in Ora-Blend
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 506
|
Shari's Burn Cream
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 507
|
Sulfadiazine 100 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 508
|
Ziprasidone Mesylate 2.5 mg/mL in Ora-Sweet Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 509
|
Compounding Robots for Intravenous Therapy in European Countries: A Review in 2020
Hecq Jean-Daniel, Soumoy Laura
|
Nov/Dec 2021
Pg. 510-514
|
Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding
Soefje Scott, Rickabaugh Keith, Rajkumar Rahul, Wall Kathryn P
|
Nov/Dec 2021
Pg. 515-522
|
Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution
Zaid Abdel-Naser, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim
|
Nov/Dec 2021
Pg. 523-527
|
| Return to Top |
